Global Proteomics | Next-Generation Proteomics | Large-Scale Proteomics

Powering precision medicine into reality

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.

OUR STORY

Transformative Insights from Discovery to Clinic

Unbiased biological insights from tissue and biofluids

Novel drug target identification and validation

Custom panels for absolute protein quantification

Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.

OUR SERVICES

High Performance Software, Peptide Kits, and Sample Preparation Reagents

Our software solutions for proteomics include Spectronaut® for DIA proteomics, SpectroDive™ for Targeted Proteomics, SpectroMine™ for DDA proteomics, and our free-of-charge QC tool QuiC™.

 

 

OUR SOFTWARE

Our peptide kits and reagents empower researchers to apply cutting-edge proteomics in-house. Discover our PQ500™ Reference Peptides for plasma proteomics quantification, our iRT kit for quality control, and our sample preparations kits.

 

OUR KITS

Latest News & Stories

News
Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Library-free and machine learning-augmented data analysis with Spectronaut® 18 yields industry-leading protein quantification and throughput for DIA proteomics. Novel[...]

READ MORE
News
Biognosys Announces Appointment of Jakob Vowinckel as Chief Officer of Scientific Operations

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the appointment of Jakob Vowinckel, Ph.D., as Chief Officer of[...]

READ MORE
Resource - Launch Pages
Spectronaut® 18: Limitless Throughput. Unparalleled Efficiency

Spectronaut® 18 solves most of the pain points of modern mass spectrometry-based projects. The new version is cloud-ready and comes with long-awaited Linux support. But that’s[...]

READ MORE
News
Biognosys Unveils Innovative Workflow for Deep and Reproducible Plasma Proteomics, Enabling Breakthroughs in Molecular Diagnostics and Drug Development

Biognosys, a leading innovator and provider of proteomics solutions, today at the American Society for Mass Spectrometry (ASMS) Annual Conference is announcing the launch of an[...]

READ MORE
News
Biognosys Reaches Technology Breakthrough for Deep Tissue Profiling with the Bruker timsTOF HT Platform

New R&D workflow achieved a total depth of over 14,600 proteins across 22 different human tissues. In the R&D study, the Bruker timsTOF HT mass spectrometer was deployed[...]

READ MORE
News
Biognosys Launches Spectronaut 18 and Presents Advances in Proteomics Depth, Sensitivity, and Scalability at the ASMS 2023 Annual Conference

Spectronaut® 18 makes DIA proteomics projects more efficient and scalable than ever for all mass spectrometry instrument types. Novel research with TrueDiscovery™[...]

READ MORE
News
Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse™ at the AACR Annual Meeting 2023

In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery™,[...]

READ MORE
News
Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics, expected to[...]

READ MORE
News
Biognosys Releases TrueTarget™ Technology Update that Enables More Effective Biopharma Drug Discovery

The improved Limited Proteolysis Mass Spectrometry (LiP-MS) proteomics technology allows for better identification of drug[...]

READ MORE

Our technological innovation and scientific expertise are fueled by an extensive network of over 25 collaborators across the life science industry and academia.

 

Our Collaborators

Join Email List

    Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

    Join the Biognosys email list to receive news and exclusive content.

    Join Email List

      Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

      Contact